After Denosumab treatment, total T cells isolated from cancer patient were reduced from 14.51 ± 3.71% to 3.88 ± 1.77% and CD4+CFSE− cell reduced from 5.32 ± 0.76% to 1.33 ± 2.31% (Fig. 7c). The gene discussed is CD4; the disease is cancer.